Infinity Pharmaceuticals, Inc. (INFI)
-NasdaqGS 24.30 
0.06(0.25%) 4:00PM EDT
| Prev Close: | 24.36 |
|---|
| Open: | 23.87 |
|---|
| Bid: | 19.18 x 2100 |
|---|
| Ask: | 25.72 x 800 |
|---|
| 1y Target Est: | 46.50 |
|---|
| Beta: | 0.84 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 23.16 - 24.82 |
|---|
| 52wk Range: | 11.02 - 50.51 |
|---|
| Volume: | 1,183,121 |
|---|
| Avg Vol (3m): | 1,099,420 |
|---|
| Market Cap: | 1.16B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.91 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Infinity to Present at Deutsche Bank's 38th Annual Health Care ConferenceBusiness Wire(Wed, May 22)
- Insiders And Funds Are Bullish On These 3 Small Cap Healthcare Stocksat Seeking Alpha(Tue, May 21)
- What’s Moving These Biotech Stocks?at Motley Fool(Sun, May 19)
- The Best- And Worst- Performing Biotech Stocks, May 10 To May 17at Forbes(Sun, May 19)
- 3 Horrendous Health-Care Stocks This Weekat Motley Fool(Sat, May 18)
- Infinity Pharma to Present Data and 2 More Heavily Traded Stocks to Followat Wall St. Cheat Sheet(Thu, May 16)
- [video] Biotech's Next Big Thing -- ASCO IIat TheStreet(Thu, May 16)
- Infinity Pharmaceuticals (INFI) Shares Cross Below 200 DMAat TheStreet(Thu, May 16)
- Infinity Announces Clinical Data to Be Presented at ASCO and ICMLBusiness Wire(Wed, May 15)
- ASCO '13 Preview: Gilead's Big Cancer Debutat TheStreet(Wed, May 15)
- INFINITY PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Tue, May 14)
- Trader sees limit to Infinity downsideoptionMONSTER(Tue, May 14)
- Infinity to Present at the UBS Global Healthcare ConferenceBusiness Wire(Tue, May 14)
- The Best- And Worst-Performing Biotech Stocks, May 3 To May 10at Forbes(Sat, May 11)
- [video] Biotech's Next Big Thing: ASCOat TheStreet(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 53.17 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.51 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.62 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | -3.24 |
|---|
Business Summary
Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need.
View More